Connecticut Health Technology Company Detect, Inc. Unveils New PCR-quality Covid-19 Rapid Test to Help Meet the Nations Testing Needs for Home, School, Work and Travel | Financial Buzz

Connecticut Health Technology Company Detect, Inc. Unveils New PCR-quality Covid-19 Rapid Test to Help Meet the Nations Testing Needs for Home, School, Work and Travel

Detect™, Inc., a Connecticut-based health technology company, unveiled its PCR-quality, at-home rapid molecular Detect™ Covid-19 Test today at a press conference at the 4Catalyzer biotech campus in Guilford, CT.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211119005782/en/

Senator Richard Blumenthal lauded the Detect Covid-19 Test that recently received an $8.1M NIH RADx contract for the scaled up manufacturing of Detect’s PCR-quality rapid at-home Covid-19 test to help meet national testing needs. (Photo: Business Wire)

Senator Richard Blumenthal lauded the Detect Covid-19 Test that recently received an $8.1M NIH RADx contract for the scaled up manufacturing of Detect’s PCR-quality rapid at-home Covid-19 test to help meet national testing needs. (Photo: Business Wire)

Detect Founder, Dr. Jonathan Rothberg, was joined by Dr. Erin Girard, Head of Clinical Affairs and Owen Kaye-Kauderer, Chief Business Officer at Detect with the support of dignitaries including; Connecticut Governor Ned Lamont, U.S. Senator Richard Blumenthal, U.S. Congresswoman Rosa Delauro And Lt. Governor Susan Bysiewicz.

The Detect Covid-19 Test is a unique molecular rapid test that combines the sensitivity of a PCR lab test with the convenience, simplicity, and scalability of a typical rapid test. Detect’s innovative technology identifies SARS-CoV-2, the virus responsible for Covid-19, at lower viral loads than antigen tests, allowing for earlier detection to mitigate pre-symptomatic spread. Unlike traditional laboratory testing, the Detect Covid-19 Test can be done entirely at home in one hour.

The Detect Covid-19 Test will be sold on Detect.com starting in December for $49 for one test and $39 for the reusable Detect Hub. Detect announced today that it will prioritize Connecticut companies and schools as Detect’s first customers to help keep the economy running and the local community safe.

As a testament to the Detect Covid-19 Test’s performance and ability to meet national testing needs, the Detect Covid-19 Test was recently selected by the highly competitive National Institutes of Health (NIH) Rapid Acceleration of Diagnostics Initiative (RADxSM) for an $8.1 million contract to scale up manufacturing.

About Detect, Inc.

Detect, Inc. (www.detect.com) is a health technology company with the mission to build tools that empower people to understand their health and make informed, timely decisions by bringing accurate testing into the home. Founded by world-renowned scientist, entrepreneur and National Medal of Technology and Innovation recipient, Dr. Jonathan Rothberg, Detect, Inc. has created an accurate, fast, and easy-to-use PCR-quality molecular Covid-19 test.

The technology also serves as a platform for future home tests, such as influenza and STIs. Detect, Inc. is part of 4Catalyzer, a health technology accelerator that strives to transform 21st century medicine by solving today’s most challenging problems across life science research tools, medical devices and therapeutics. To learn more, visit: detect.com and 4catalyzer.com.

The Detect Covid-19 Test has not been FDA cleared or approved but has been authorized by FDA under EUA. This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of Covid-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated, or authorization is revoked sooner.

This project is supported by the NIH Rapid Acceleration of Diagnostics (RADxSM) initiative and has been funded in whole or in part with federal funds from NIBIB, NIH, Department of Health and Human Services, under Contract No. 75N92022C00002.

Contacts

Media:

Shawna Marino

press@detect.com

Opt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!